Breast cancer drug linked to increased bone loss
In a nested safety substudy of 351 postmenopausal women in a Canadian trial of exemestane for breast cancer prevention (an indication not approved in Australia), aged-related BMD was three times worse in the intervention compared to placebo group despite vitamin supplementation.
Pfizer Australia noted that reduction in BMD was specified in the PI. Women at risk during adjuvant treatment should have regular bone densitometry, a spokesperson said.
Lancet Oncology 2012, online 7 Feb